Expanded Label Officially Makes Bempedoic Acid a CVD Prevention Medication
The FDA approved label expansions for bempedoic acid (Nexletol) and bempedoic acid/ezetimibe (Nexlizet) so they can be used more broadly as cardiovascular prevention drugs, Esperion announced Friday. Based on the CLEAR Outcomes trial, the two adenosine triphosphate (ATP) citrate lyase inhibitor drugs are now indicated for adults with either established atherosclerotic cardiovascular disease (CVD) or […]
Bempedoic Acid Gets ‘Huge’ Win for Primary Prevention in the Statin-Intolerant
SAN DIEGO — Bempedoic acid (Nexletol) prevented cardiovascular events in high-risk, statin-intolerant patients who had not yet had an event, a subgroup analysis from the CLEAR Outcomes trial confirmed. In these patients, bempedoic acid was associated with a large decrease in risk of major adverse cardiovascular events (MACE) compared with placebo over a median 39.9 […]
Bempedoic Acid Proves Clinical Benefits for the Statin-Intolerant
NEW ORLEANS — Bempedoic acid (Nexletol) provided compelling clinical benefit in terms of primary and secondary cardiovascular prevention for statin-intolerant patients who need cholesterol lowering, according to the CLEAR Outcomes trial. Cementing its place in the arsenal of nonstatin therapies, the ATP citrate lyase inhibitor met the primary endpoint in reducing major adverse cardiovascular events […]